Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 2,407 Shares of Company Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Vanina de Verneuil sold 2,407 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $11.10, for a total value of $26,717.70. Following the completion of the sale, the executive vice president owned 110,193 shares of the company’s stock, valued at approximately $1,223,142.30. The trade was a 2.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Verneuil Vanina De also recently made the following trade(s):

• On Monday, November 2nd, Vanina de Verneuil sold 1,343 shares of Vir Biotechnology stock. The stock was sold at an average price of $11.33, for a total value of $15,216.19.

Vir Biotechnology Stock Up 4.9%

NASDAQ VIR opened at $11.77 on Thursday. Vir Biotechnology, Inc. has a 52 week low of $4.82 and a 52 week high of $12.19. The company has a market capitalization of $1.99 billion, a P/E ratio of -6.33 and a beta of 1.70. The stock’s 50-day moving average price is $11.02 and its 200-day moving average price is $9.56.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.18. The company had revenue of ($0.19) million for the quarter, compared to the consensus estimate of $0.98 million. The company’s revenue was down 178.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.17) earnings per share. Research analysts anticipate that Vir Biotechnology, Inc. will post -1.84 EPS for the current year.

More Vir Biotechnology News

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Vir reported a Q3 loss of $0.57 per share, better than analysts’ expected loss of roughly $0.75–$0.80 and the $1.17 loss a year earlier. The improving loss may support investor sentiment. Zacks Q3 results
• Neutral Sentiment: Management said it expects to report topline results from the ECLIPSE 1 hepatitis delta trial this quarter and highlighted additional oncology catalysts. These events could be important stock drivers, but their impact will depend on the data and updates. Vir corporate update and Q3 results
• Neutral Sentiment: An executive sold a small number of shares under a pre-arranged trading plan to cover tax withholding on vested equity awards. The stated reason and limited size make the transaction less informative as a signal about the company’s outlook. SEC filing
• Negative Sentiment: Revenue was negative $0.19 million, missing analysts’ estimate of $0.98 million and declining 178.3% year over year. The revenue shortfall tempers the earnings beat. MarketBeat Q3 results

Hedge Funds Weigh In On Vir Biotechnology

A number of hedge funds have recently made changes to their positions in VIR. Oregon Public Employees Retirement Fund grew its position in shares of Vir Biotechnology by 3.3% during the third quarter. Oregon Public Employees Retirement Fund now owns 28,468 shares of the company’s stock worth $318,000 after purchasing an additional 900 shares in the last quarter. ProShare Advisors LLC raised its stake in Vir Biotechnology by 6.4% during the 3rd quarter. ProShare Advisors LLC now owns 24,507 shares of the company’s stock valued at $274,000 after purchasing an additional 1,464 shares during the period. Allspring Global Investments Holdings LLC raised its stake in Vir Biotechnology by 4.1% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 55,135 shares of the company’s stock valued at $616,000 after purchasing an additional 2,164 shares during the period. Maryland State Retirement & Pension System lifted its holdings in Vir Biotechnology by 19.8% in the 1st quarter. Maryland State Retirement & Pension System now owns 16,163 shares of the company’s stock worth $145,000 after purchasing an additional 2,668 shares in the last quarter. Finally, Fiduciary Financial Advisors purchased a new position in Vir Biotechnology in the 2nd quarter worth approximately $29,000. Institutional investors own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a report on Friday, October 2nd. Wall Street Zen raised shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a research note on Thursday, August 6th. Raymond James Financial restated a “strong-buy” rating on shares of Vir Biotechnology in a research report on Monday, September 28th. Finally, HC Wainwright lifted their target price on shares of Vir Biotechnology from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $21.86.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical-stage immunology company focused on developing medicines to prevent and treat serious infectious diseases and other immune-related conditions. The company uses antibody engineering, immunologic approaches and other technologies to identify and advance therapies designed to harness or modify the immune system.

Vir’s research and development programs have included treatments and vaccines for hepatitis B, human immunodeficiency virus (HIV), influenza and other infectious diseases.